Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03932721 Completed - Clinical trials for Diabetes Mellitus, Type 2

EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial

EXCEED-BHS3
Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

Based on the current evidence, empagliflozin could reduce cardiovascular morbidity and mortality in Diabetes Mellitus Type 2 (T2DM). Anti-PCSK9 therapy (evolocumab) can reduce the major cardiovascular events incidence in secondary prevention individuals, some of them presenting T2DM. The beneficial effect of the combined use of these two agents in T2DM remains unknown. Evaluating the effect of evolocumab on top of the best of care therapy for T2DM, including empaglifozin, on endothelial function may indicate the existence of some benefit related to cardiovascular outcomes.

NCT ID: NCT03931785 Completed - Clinical trials for Irritable Bowel Syndrome With Diarrhea (IBS-D)

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

NCT ID: NCT03931603 Completed - Clinical trials for Endometriotic Parietal Involvement of the Rectosigmoid

Endometriosis of the Recto-sigmoid: MRI (Magnetic Resonance Imaging) Criteria Predictive of Shaving or Segmental Resection

Start date: September 1, 2017
Phase:
Study type: Observational

Evaluate MRI criteria predictive of the type of surgery to be performed for an "in sano" resection of endometriotic involvement of the recto-sigmoid by a resection without opening of the rectal mucosa ("shaving") versus a segmental resection.

NCT ID: NCT03931330 Completed - Clinical trials for Irritable Bowel Syndrome

Does Improving Vagal Tone Increase Mitochondrial Bioenergetics

Start date: February 6, 2019
Phase: N/A
Study type: Interventional

This study evaluates the effect of auricular neurostimulation on mitochondrial bioenergetics and inflammation through vagal nerve modulation via non-invasive percutaneous electrical nerve field stimulator in children with functional gastrointestinal disorders.

NCT ID: NCT03931291 Completed - Clinical trials for Acute Myeloid Leukemia or Myelodysplastic Syndromes

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Start date: September 16, 2019
Phase: Phase 2
Study type: Interventional

A multi-center, open label, Phase II clinical trial to assess the safety and efficacy of APR-246 in combination with azacitidine as maintenance therapy after allogeneic HSCT (hematopoietic stem cell transplant) for patients with TP53 mutant AML or MDS.

NCT ID: NCT03930914 Completed - Clinical trials for Postural Orthostatic Tachycardia Syndrome

Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome

POTS
Start date: November 4, 2019
Phase: N/A
Study type: Interventional

Postural orthostatic tachycardia (POTS) is characterized by abnormalities in the autonomic nervous system in the body. The autonomic nervous system controls and regulates body functions such as heart rate, breathing, digestion, and more. The investigator has shown that patients with POTS have higher cardiovascular and adrenergic activating autoantibodies (AAb), which likely changes the normal make-up of POTS. There are autoantibodies that have been suggested by a few reports of their presence in POTS, but their role different aspects of POTS is unknown. The study will look at the body's responses in patients with POTS. The crossover study design is to have half of the patients will start with sham followed by active stimulation and half will start by active followed by sham stimulation. It is anticipated that results will provide a potential therapeutic approach based on the understanding of POTS.

NCT ID: NCT03930641 Completed - Clinical trials for Neovascular Age Related Macular Degeneration

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

Start date: May 23, 2019
Phase: Phase 3
Study type: Interventional

This was a multicenter, open label study that is designed to evaluate the safety of brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular degeneration and to support collection of observations of the prefilled syringe use for intravitreal injection.

NCT ID: NCT03930173 Completed - Clinical trials for Secondary Malignant Neoplasm of Brain and Cerebral Meninges

18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis

Start date: July 2, 2019
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate whether 18F-fluciclovine PET/CT of the brain, is able to distinguish radiation necrosis from tumor progression in cases where MRI is inconclusive. 18F-fluciclovine is an FDA approved radioactive diagnostic agent and is injected into the participant and then taken up by cancer cells, which can then be visualized with a PET/CT scan. 18F-fluciclovine is FDA approved for the detection of recurrent prostate cancer, but is still investigational for the purposes of this study.

NCT ID: NCT03930017 Completed - Influenza Clinical Trials

Pregnancy, Arsenic and Immune Response

PAIR
Start date: October 14, 2018
Phase:
Study type: Observational

As the global availability of vaccines increases, and reaches areas disproportionately affected by arsenic and malnutrition, resolving questions about potential environmental and biologic barriers to maternal immunization has become increasingly urgent. It is not known whether arsenic, a known developmental toxicant, can alter maternal immune responses to vaccination and whether exposure to arsenic during pregnancy can impair the transfer of maternal vaccine-induced antibody to the newborn. Moreover, factors known to affect arsenic metabolism and toxicity outcomes, particularly micronutrients critical in one-carbon metabolism, have not been evaluated in studies of arsenic immunotoxicity and vaccine-induced protection in mothers and their newborns. The objective in this study is to investigate whether maternal arsenic exposure and one-carbon metabolism micronutrient deficiencies alter maternal and newborn measures of vaccine-induced protection, respiratory morbidity, and systemic immune function following influenza vaccination during pregnancy.

NCT ID: NCT03929445 Completed - Clinical trials for Intubation;Difficult

Bougie Assisted Endotracheal Intubation in Air-Q Intubating Laryngeal Mask And Fastrach Intubating Laryngeal Mask

Start date: January 2017
Phase: N/A
Study type: Interventional

This study aims to compare using bougie as an assistant for endotracheal intubation through Air-Q and Fastrach intubating laryngeal mask devices when blind intubation fails as attempt to increase its success rate.